NeuroSense Secures Australian Patent for PrimeC, Extending Exclusivity Through 2042
NeuroSense received Australian patent No. 2022370513 for PrimeC composition comprising ciprofloxacin and celecoxib, extending exclusivity through October 2042 alongside the US patent. This strengthens global IP for its Phase 3-ready ALS and Alzheimer’s drug candidate, supporting long-term commercialization prospects.
1. Australian Patent Granted
NeuroSense obtained Australian Patent No. 2022370513, titled "Compositions Comprising Ciprofloxacin and Celecoxib," covering its PrimeC fixed-dose formulation and extending protection in Australia through October 2042.
2. Strengthening Global IP Portfolio
This grant builds on U.S. Patent 12,097,185 and reinforces exclusivity across key markets, underpinning NeuroSense’s strategy to secure a durable intellectual property estate for PrimeC’s synchronized, extended-release therapy.
3. Phase 3-Ready Candidate Supports Commercialization
PrimeC combines ciprofloxacin and celecoxib in an engineered extended-release formulation targeting neuroinflammation and iron dysregulation; it is Phase 3-ready in ALS and poised for pivotal development and future commercialization.